<DOC>
	<DOCNO>NCT00158041</DOCNO>
	<brief_summary>Amifostine radioprotective drug approve US FDA administration prior radiation treatment use intravenous route . The study evaluate safety amifostine administer subcutaneously . The four targeted toxicity nausea/vomiting , hypotension , generalize skin rash , injection-site skin reaction .</brief_summary>
	<brief_title>Subcutaneous Amifostine Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Institutional criterion administration amifostine Radiation therapy ECOG PS least 2 No distant mets Granulocyte count great 2000 Platelet count great 100,000 Creatinine less 2.0 Allergy amifostine Life expectancy le 6 mos Investigational drug within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Amifostine</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Nausea</keyword>
	<keyword>Hypotension</keyword>
	<keyword>Rash</keyword>
</DOC>